Opportunity ID: 252857

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-AR-14-016
Funding Opportunity Title: Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus: Network Research Sites (UH2/UH3)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.846 — Arthritis, Musculoskeletal and Skin Diseases Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Mar 21, 2014
Last Updated Date:
Original Closing Date for Applications: May 21, 2014
Current Closing Date for Applications: May 21, 2014
Archive Date: Jun 21, 2014
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Public and State controlled institutions of higher education
Independent school districts
Small businesses
County governments
Private institutions of higher education
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities
City or township governments
Native American tribal governments (Federally recognized)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
State governments
Native American tribal organizations (other than Federally recognized tribal governments)
Special district governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this FOA is to solicit applications for the Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis (RA) and Lupus Network Research Sites. The AMP RA and Lupus Network is designed to ascertain and define shared and disease-specific biological pathways in order to identify relevant drug targets for the treatment of autoimmune diseases. This program will involve an enhanced systems-level understanding of gene expression and signaling in target tissues from affected end organs and peripheral blood cells.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-14-016.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email: FBOWebmaster@OD.NIH.GOV

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-C FORMS-C PKG00194241 Apr 21, 2014 May 21, 2014 View

Package 1

Mandatory forms

252857 RR_SF424_2_0-2.0.pdf

252857 PHS398_ResearchPlan_2_0-2.0.pdf

252857 PHS398_CoverPageSupplement_2_0-2.0.pdf

252857 RR_Budget_1_3-1.3.pdf

252857 RR_KeyPersonExpanded_2_0-2.0.pdf

252857 RR_OtherProjectInfo_1_3-1.3.pdf

252857 PerformanceSite_2_0-2.0.pdf

Optional forms

252857 PlannedReport-1.0.pdf

252857 PHS398_CumulativeInclusionReport-1.0.pdf

252857 RR_SubawardBudget30_1_3-1.3.pdf

2025-07-09T10:11:08-05:00

Share This Post, Choose Your Platform!

About the Author: